Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990180 | 0.88 | LMNA (0.54) | LMNATSHRL3MBTL1THRBCA1 | |
| SCHEMBL21990124 | 0.86 | CA12 (0.54) | LMNATSHRL3MBTL1THRBCA12 | |
| SCHEMBL21990130 | 0.83 | CA12 (0.53) | LMNATSHRL3MBTL1CA12CA1 | |
| SCHEMBL20594732 | 0.82 | LMNA (0.58) | LMNATSHRL3MBTL1THRBCA12 | |
| SCHEMBL21990161 | 0.81 | CA1 (0.49) | LMNATSHRL3MBTL1CA12CA1 | |
| SCHEMBL21990137 | 0.78 | LMNA (0.58) | LMNATSHRL3MBTL1THRBMAPT | |
| SCHEMBL21990046 | 0.77 | POLB (0.73) | LMNATHRBMAPTPOLBHTT | |
| SCHEMBL18954909 | 0.76 | ALDH1A1 (0.71) | LMNATHRBCA12CA1CA2 | |
| SCHEMBL281572 | 0.74 | TGM2 (0.57) | LMNAMAPTTP53 | |
| SCHEMBL281270 | 0.73 | CES1 (0.63) | TSHRMAPTTP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | LMNA 4251/4885TSHR 4194/4885L3MBTL1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.